These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 26279284)

  • 1. Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity.
    Clewemar Antonodimitrakis P; Sundin A; Wassberg C; Granberg D; Skogseid B; Eriksson B
    Neuroendocrinology; 2016; 103(3-4):345-53. PubMed ID: 26279284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours.
    Dilz LM; Denecke T; Steffen IG; Prasad V; von Weikersthal LF; Pape UF; Wiedenmann B; Pavel M
    Eur J Cancer; 2015 Jul; 51(10):1253-62. PubMed ID: 25935542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment with streptozocin/5-fluorouracil chemotherapy in patients with metastatic pancreatic neuroendocrine tumors: Case series.
    Müller C; Kreissl MC; Klose S; Krause A; Keitel V; Venerito M
    Medicine (Baltimore); 2022 Jan; 101(4):e28610. PubMed ID: 35089197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relevance of dihydropyrimidine-dehydrogenase and thymidylate-synthase in patients with pancreatic neuroendocrine neoplasms treated with 5-FU-based chemotherapy.
    Krug S; Boch M; Nimphius W; Gress TM; Michl P; Rinke A
    Pancreatology; 2017; 17(1):139-145. PubMed ID: 28027897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors.
    Krug S; Gress TM; Michl P; Rinke A
    Digestion; 2017; 96(2):67-75. PubMed ID: 28728148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy.
    Shibuya H; Hijioka S; Sakamoto Y; Ito T; Ueda K; Komoto I; Kobayashi N; Kudo A; Yasuda H; Miyake H; Arita J; Kiritani S; Ikeda M; Imaoka H; Ueno M; Kobayashi S; Furuta M; Nagashio Y; Murohisa G; Aoki T; Matsumoto S; Motoya M; Azemoto N; Itakura J; Horiguchi S; Yogi T; Kawagoe T; Miyaoka Y; Imamura F; Senju M; Arioka H; Hara K; Imamura M; Okusaka T
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):661-668. PubMed ID: 30054710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.
    Turner NC; Strauss SJ; Sarker D; Gillmore R; Kirkwood A; Hackshaw A; Papadopoulou A; Bell J; Kayani I; Toumpanakis C; Grillo F; Mayer A; Hochhauser D; Begent RH; Caplin ME; Meyer T
    Br J Cancer; 2010 Mar; 102(7):1106-12. PubMed ID: 20234360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended cycle streptozotocin/5-FU chemotherapy for maintenance therapy in pancreatic neuroendocrine tumors.
    Schrader J; Henes FO; Blaeker M; Zimmermann-Fraedrich K; Pace A; Perez D; Izbicki JR; Lohse AW; Benten D
    Endocrine; 2019 Aug; 65(2):460-467. PubMed ID: 31037707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors.
    Prakash L; Bhosale P; Cloyd J; Kim M; Parker N; Yao J; Dasari A; Halperin D; Aloia T; Lee JE; Vauthey JN; Fleming JB; Katz MH
    J Gastrointest Surg; 2017 Jan; 21(1):155-163. PubMed ID: 27634306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors.
    Rogers JE; Lam M; Halperin DM; Dagohoy CG; Yao JC; Dasari A
    Neuroendocrinology; 2022; 112(1):34-42. PubMed ID: 33434908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment Stratification.
    Krug S; Boch M; Daniel H; Nimphius W; Müller D; Michl P; Rinke A; Gress TM
    PLoS One; 2015; 10(12):e0143822. PubMed ID: 26630134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan.
    Aoki T; Kokudo N; Komoto I; Takaori K; Kimura W; Sano K; Takamoto T; Hashimoto T; Okusaka T; Morizane C; Ito T; Imamura M
    J Gastroenterol; 2015 Jul; 50(7):769-75. PubMed ID: 25348496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors.
    Krug S; Boch M; Rexin P; Gress TM; Michl P; Rinke A
    Anticancer Res; 2017 May; 37(5):2491-2500. PubMed ID: 28476818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy.
    Lahner H; Mathew A; Klocker AL; Unger N; Theysohn J; Rekowski J; Jöckel KH; Theurer S; Schmid KW; Herrmann K; Führer D
    Endocrine; 2022 Jan; 75(1):293-302. PubMed ID: 34480724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of weekly streptozocin and oral S-1 treatment for patients of unresectable or metastatic pancreatic neuroendocrine neoplasms.
    Ono H; Kudo A; Akahoshi K; Ogura T; Ogawa K; Ban D; Tanaka S; Tanabe M
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):793-799. PubMed ID: 31844980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single institution experience of streptozocin/fluorouracil combination chemotherapy: a case series.
    Naidoo J; O'Toole D; Kennedy MJ; Reynolds JV; O'Connor M; O'Byrne K
    Ir J Med Sci; 2012 Jun; 181(2):211-4. PubMed ID: 22048868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic chemotherapy for pancreatic neuroendocrine tumors.
    Okusaka T; Ueno H; Morizane C; Kondo S; Sakamoto Y; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M
    J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):628-33. PubMed ID: 25940377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE).
    Roquin G; Baudin E; Lombard-Bohas C; Cadiot G; Dominguez S; Guimbaud R; Niccoli P; Legoux JL; Mitry E; Rohmer V; Ruszniewski P; Walter T; Ducreux M; Couvelard A; Scoazec JY; Ramond-Roquin A; Caroli-Bosc FX; Hentic O
    Neuroendocrinology; 2018; 106(1):38-46. PubMed ID: 28152531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)--a phase II non-randomised trial.
    Ducreux M; Dahan L; Smith D; O'Toole D; Lepère C; Dromain C; Vilgrain V; Baudin E; Lombard-Bohas C; Scoazec JY; Seitz JF; Bitoun L; Koné S; Mitry E
    Eur J Cancer; 2014 Dec; 50(18):3098-106. PubMed ID: 25454412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
    Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
    JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.